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Abstract
Used in the psoriasis therapy for over 30 years, methotrexate belongs to the non‐bio‐
logical medication class. Its continued use must be studied in the context of the modern 
unprecedented powerful pharmacological and medical development, due to the particu‐
larly, even uniquely fast development of biologicals, which assume an extremely impor‐
tant role in cutting‐edge medicine. This status has turned biosimilars and all related 
matters into an outstanding challenge not only for researchers worldwide but also for 
other medicinal product‐associated fields such as development of regulatory standards 
and pharmacovigilance, to mention the most important. However, against a comparable 
high‐risk background, compounded by the additional danger of serious cumulative tox‐
icity, methotrexate therapy continues to be recommended mainly for patients suffering 
from severe psoriasis, seriously affecting their quality of life.
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1. Introduction
Known since ancient times (judging by descriptions of typical lesions found in mummified 
bodies, as early as the Christian era), psoriasis is a frequent autoimmune disease mostly causing 
chronic inflammation of the skin, through other manifestations are not uncommon. Psoriasis is 
mediated by T‐cells and as such is the more frequently encountered human disease of its class. 
Since the very beginning and as far as the late Middle Ages, because of its mistaken diagnosis as 
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leprosy and subsequent isolation of patients, it was accompanied by significant social and eco‐
nomic burden. Further in history, at the beginning of the nineteenth century, scientists finally 
observed and mentioned its association with joint impairment (now known as arthropathic 
psoriasis) (1818, Jean‐LouisAlibert) [1, 2]. The socio‐economic impact of psoriasis has however 
been preserved [3], in the context of the generally severely impaired quality of life, as well as of 
forms refractory to treatment and frequent occurrence of comorbidities, accentuated by the fact 
that permanent cure for psoriasis is a goal yet to be accomplished.
Nowadays, some 2–3% of the population is affected, with too little dissimilarity between the 
two genders. From the perspective of race factors, studies conducted worldwide have shown 
0.7% prevalence among individuals of African descent, relatively low frequency in native 
South‐American populations as well as bimodal distribution as regards the age for its onset [4].
With regard to psoriasis‐associated risks suggested by the results of epidemiological studies, 
the prevalence of various comorbidities and mortality seems rather high [5, 6]. Among the 
related comorbidities, mentioning due to psoriatic arthritis, chronic inflammatory intestinal 
disease and psychiatric and psychosocial disorders, as the most common; however, cardio‐
vascular comorbidities (obesity, diabetes, dyslipidemia, hypertension as well as coronary dis‐
ease) [7–10] have also more recently been shown to arise from psoriasis‐induced metabolic 
changes. In this respect, research has found increased myocardial infarction risk for younger 
patients suffering from severe forms of psoriasis [11].
The clinical profile in psoriasis consists of erythematous and scaling lesions, distributed in 
various patterns and regions of the body. At the same time, a range of individual clinical 
phenotypes may be noted such as vulgar, pustular, inverted, erythrodermic and guttate. In 
5–20% of the cases, psoriasis involves the joints and the nails [12]. A comparative look at pre‐
mature onset or type I and type II or delayed onset psoriasis (arising between the ages of 50 
and 60 or later), one should notice the former's more frequent family background of DR7 and 
HLA‐Cw6 and the disease, as well as type I tendency to more significant dissemination and 
more frequent relapses [4, 12].
Psoriasis is known to be triggered and/or aggravated by such factors as trauma, drugs, infec‐
tions, alcoholism and smoking [13, 14]. Given that psoriasis may not be yet cured, progress 
has mainly focused on suppression of the systemic inflammatory response and general dis‐
ease signs, which are considered sufficient to allow symptom‐free conditions for longer peri‐
ods of time, as well as on development of therapies for accompanying diseases.
Not all has been fully clarified in relation to psoriasis pathogenesis mainly due to the involve‐
ment of complex factors of immunologic, environmental and genetic nature. Immune contri‐
bution to pathogenesis may be derived from the finding that former bone marrow transplant 
recipients from a donor with psoriasis also developed the disease; this has been further cor‐
roborated with the improvement of the disease observed subsequent to ablation followed by 
bone marrow transplant from psoriasis‐free patients as well as by successful therapy using 
methotrexate, TNF‐α inhibitors and cyclosporine [15–17].
Keratinocyte dysfunction is a result from tissue damage triggered by anomalous immuno‐
logical response. This dysfunction can be observed in the more than 50 times increase of the 
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mitotic activity of basal keratinocytes in the psoriatic skin, resulting in reduced migration 
time (3–5 days as compared to the regular 28–30 days) from the basal to the corneal stratum 
[15, 18]. Histopathological examinations typically reveal parakeratosis, acanthosis, hyperker‐
atosis, accompanied by loss of the granular layer, elongation of epidermal ridges, vascular 
dilation, dermal‐epidermal infiltrate and angiogenesis. In addition, which is a key for his‐
topathological diagnosis, Munro's micro‐abscesses are present, consisting of a sub‐corneal 
aggregation of neutrophils [16, 19].
2. An overview of psoriasis therapy
Depending on the type and degree of severity as well as on the area of skin involved, age 
of the patient, costs, therapeutic management of psoriasis mainly consists of phototherapy, 
involving UV exposure of the skin, topical approaches and systemic medication but selection 
of the most effective treatment from the numerous therapeutic approaches is challenging.
Mainly consisting of application of ointments and creams to the skin, topical therapy is gen‐
erally resorted to in cases of mild disease and formerly relied on use of keratolytic agents or 
emollients intended to help shed off or hydrate the skin. In keeping with further research 
developments, this type of treatment has increasingly targeted underlying proliferation of 
T‐cell, therefore including vitamin D, coal tar, retinoids and topical calcineurin inhibitors.
For more severe forms, light‐therapy and systemic treatments have been developed. Medication 
with systemic action administered orally or by injection includes the use of conventional 
drugs such as cyclosporine, acitretin, methotrexate and hydroxyurea, however associates with 
more prominent risk of serious adverse reactions, particularly for long‐term treatment. One 
approach that has proved successful in improved and prompter effectiveness has consisted in 
combining all such therapies, achieving suppression of the disease and mitigation of adverse 
reactions. More recently, this has further been boosted by development of new, more targeted 
drug carrier systems. Development and increase of biological drugs and gene therapy have 
currently further supplemented therapeutic approaches with essentially ground‐breaking new 
modalities, though none of them curative.
3. Medicinal products for systemic medications
3.1. Non‐biological medication
3.1.1. Methotrexate – Overview
Methotrexate (MTX), a folic acid antagonist, has been used as non‐biological medication in 
psoriasis therapy for longer than 30 years. Its use has proved successful in both treatment of 
psoriasis as such and of psoriatic arthritis and nail disease.
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Though first used before introduction of routine conduct of randomized clinical trials and 
therefore still wanting in efficacy and safety data MTX is widely used in both mono‐ and com‐
bination dermatologic therapy predominantly for psoriatic arthritis and psoriasis, but also for 
dermatomyositis, sarcoidosis and pyoderma gangrenosum [17, 20, 21].
First authorised for psoriatic therapy in 1972, methotrexate was accordingly indicated, with 
no specification of the minimum body surface, for severe, refractory to topical therapy and 
phototherapy, and debilitating forms, therefore used in patients with functional disability 
arising from unresponsive scalp disease, palmoplantar disease or other severe, limited pso‐
riasis forms.
Used in line with the standards established in guidelines published as early as 1972 and con‐
tinually updated up to 1998 [22], MTX has proved successful in the treatment of pustular, 
plaque, guttate and erythrodermic psoriasis.
Furthermore, in 1988, MTX further received approval for the treatment of rheumatoid arthri‐
tis, the dedicated standards developed by the American College of Rheumatology (ACR), 
not requesting prior liver biopsy, which in fact were later eliminated from the guidelines for 
dermatologic use as well. However, the latter do not mention mandatory patient monitoring 
for possible liver toxicity resulting from methotrexate use [23]. At the same time, the issue of 
possible MTX liver toxicity is counteracted by such means as appropriate individual evalua‐
tion of patients’ medical status, disease severity, quality of life, and psychological standing for 
proper selection and monitoring.
At the same time, MTX is used for cancer treatment, although in much larger dose than for 
dermatologic purposes:
Common approaches for MTX administration are as follows [24]:
• Conventional low‐dose therapy, as follows:
 ‐ dose: 15–50 mg/m2 body surface area;
 ‐ frequency: weekly, as one/several doses;
 ‐ administration route: intramuscularly/intravenously.
Head and neck cancer:
 ‐ dose: 40–60 mg/m2 body surface area;
 ‐ frequency: weekly, once;
 ‐ administration route: intravenous bolus injection.
• Intermediate‐dose therapy, as follows:
 ‐ dose: 100–1000 mg/m2 body surface area;
 ‐ frequency: single dose.
Cancer of the bladder, advanced squamous epithelial: intermediate dose, 100–200 mg/m2.
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• High‐dose therapy, as follows:
 ‐ mostly in malignant diseases, e.g. acute lymphatic leukaemia, malignant lymphoma, meta‐
static choriocarcinoma, osteogenic sarcoma;
 ‐ dose: 1000 mg or more/m2 body surface area;
 ‐ frequency: over a 24‐hour period.
Folinic acid should be started at 10–15 mg (6–12 mg/m2), 12–24 hours after MTX therapy 
initiation.
Since 1998, a therapeutic approach of psoriasis has undergone remarkable changes, brought 
about by unprecedented expansion of basic and clinical research, leading to development 
of biologic agents such as alefacept, efalizumab, etanercept, infliximab, adalimumab and 
ustekinumab, which have all been approved for the treatment of psoriasis.
In comparison to biological drugs, even considering the costs of pre‐treatment liver biopsy and 
blood monitoring, MTX is significantly less expensive, which explains why proof of intolerance 
or lack of responsiveness to methotrexate is a prerequisite for certain insurance companies.
However, considering the long‐term aspect of psoriasis management and the associated issue 
of possible haematologic or hepatic toxicity with methotrexate, and not withstanding reduced 
costs, targeted therapies allowed by biologic drugs are more viable alternative treatment 
options to methotrexate.
3.1.2. Efficacy of methotrexate in the treatment of psoriasis
MTX has been used effectively on patients suffering from widespread forms of psoriasis, 
unresponsive to phototherapy or topical therapy or disabling psoriasis [22].
The pharmacological action of MTX interferes with DNA consists and suppresses the immune 
system, resulting in notable slowing down the accumulation of dead skin cells.
Regarding actual administration, MTX is taken orally, in one weekly dose, either as a single 
dose or as three doses separated by 12 hours. Folic acid (a B vitamin) may also be adminis‐
tered as a concomitant supplement.
Generally, to reduce MTX toxicity, 5–10 mg folic acid weekly is recommended by most rel‐
evant reviews and guidelines; however, there is general agreement among them that ‘the 
evidence base is insufficient to determine the optimum dose’ and that there may be ‘potential 
need for higher dosages, with the currently higher dosed methotrexate’ [25].
Effects on the disease can be observed within several weeks from treatment initiation, as the 
condition of the skin starts to improve, full improvement to set in regularly in 2–3 months’ 
time. To completely clear the disease, possible remaining plaques may be treated by topical 
application of other specific medication or UVB/PUVA phototherapy may be applied. This is 
also recommended when the MTX dose has to be reduced for toxicity reasons, combination 
with additional medication, e.g. a retinoid, is also an option.
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Patients on MTX require close monitoring consisting of chest X‐rays, regular blood tests or 
liver biopsy for more conclusive outcomes, as a result of possible damage to the liver and 
kidney functions or decrease of the body's capacity to produce white and red blood cells and 
platelets. Also, it should be borne in mind that MTX and specific metabolites intracellular 
accumulation leads to depletion of the folate store [26, 27].
The risk of adverse reactions may be dose dependent or vary with the route of adminis‐
tration (lower in parenteral administration) [28]. However, care should be exercised since 
doses under 15 mg/week may prove ineffective considering the therapeutic goal for disease 
control.
3.1.3. MTX contraindications and adverse reactions
Generally, MTX use is restricted by the risk of organ toxicity. Therefore, use of MTX for pso‐
riasis is an absolute contraindication in:
(a) Pregnancy or by women planning to become pregnant and their partners, because of MTX 
teratogenic effect. In fact, conception is to be avoided both during methotrexate therapy 
and for at least 3 months afterwards for males or for one ovulatory cycle for females;
(b) Nursing;
(c) Significant leukopenia, anaemia or thrombocytopenia.
In a number of cases, MTX may not be reasonably used for psoriasis treatment. Thus, MTX 
should be avoided for patients with [29]:
(a) Active or recurrent hepatitis, cirrhosis or markedly deteriorated liver function, in the con‐
text of known liver toxicity potential of MTX; therefore, function tests are standard, as 
well as close monitoring in the case elevations are observed.
In the same respect, excessive alcohol consumption is also an issue—despite the scarcity 
of data to substantiate any definite limits for alcohol, which allows recommendations to 
vary from total prohibition of alcohol to permitted consumption of no more than drinks/
day, liver damage associated with a history of alcoholism is undeniably problematic.
Also, in relation to MTX potential for liver toxicity, the drug is contraindicated in the case 
of other hepatotoxic drugs are used at the same time, which usually requires even closer 
liver function monitoring;
(b) Abnormal kidney functioning; a significantly lower dose may be required, taking into 
account that the kidneys are the main excretion route for MTX (ca. 85%);
(c) Active forms of infectious diseases, particularly chronic infections such as advanced 
HIV infection or active untreated tuberculosis, prone to exacerbation resulting from 
MTX immunosuppressive effects; therefore, in the case of patients on MTX developing 
an infection, the drug may be withheld temporarily.
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The same may apply for immunosuppressed patients, but not to those using biologic thera‐
pies, for instance.
(d) Obesity, with >30 body mass index;
(e) Diabetes mellitus;
(f) Recent vaccination, particularly for live vaccines;
(g) Unreliable patient, which once more highlights the importance of psychological evalua‐
tion for patient selection for MTX therapy.
In the context of the above relative contraindications, cases may however arise when the ben‐
efits of MTX outweigh its inherent risks. Therefore, therapy decisions should be made for 
each individual patient, based on their specific status and background. For an obese patient 
with diabetes, for instance, who would benefit from short‐term MTX therapy, the relative 
contraindication may be waived due to the short‐term character of the therapy.
In MTX, there are three primary concerns for the physician, i.e. myelosuppression, hepa‐
totoxicity and pulmonary fibrosis, as shown in a study conducted by the United Kingdom 
Committee on the Safety of Medicines on 164 possibly methotrexate‐associated deaths 
reported during 1969–2004. Among these, 41% were attributable to myelosuppression, 18% 
to pulmonary fibrosis and only 0.5% to liver toxicity [30]. Though the risk of MTX‐associ‐
ated pulmonary fibrosis in the treatment of psoriasis is much lower than for rheumatoid 
arthritis (explaining why chest X‐rays are not mandatory for routine baseline studies), 
development of pulmonary symptoms should be duly taken into account and pulmonary 
fibrosis should be considered [31, 32].
Hepato‐ and haematologic MTX effects may commonly manifest such as anorexia, nausea, 
stomatitis, malaise and fatigue, mainly right on administration. As shown by clinical experi‐
ence, such manifestations may be avoided or alleviated by changing the administration route 
to subcutaneous or intramuscular injection or the time of administration to bedtime, supple‐
mentation of folates or dose‐splitting.
Other adverse reactions have lately been identified and researched due to the more thorough 
study of the disease triggered by the introduction of biologic therapy and more sustained con‐
duct of post‐marketing surveillance studies, formerly obscured by the lack of closer scrutiny 
of MTX. Thus, such reactions as reactivation of hepatitis and tuberculosis and development 
of lymphoma (especially associated with the Epstein‐Barr virus) have also been added to the 
list of potential toxicities [33–36].
In addition, as reported from a recent study conducted in the general population, a 50% 
increased risk of malignancy could also be observed, more precisely, the respective rise 
related to a fivefold increase in non‐Hodgkin lymphoma, a threefold increase in melanoma 
and an almost threefold increase in lung cancer [37], which requires mandatory increased 
physician care for the unexpected in patients on immunosuppressive therapy in general.
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Unexpected benefits are also possible in MTX side effects, such as its demonstrated protec‐
tive effect as anti‐inflammatory medication against cardiovascular disease in certain patients 
[38, 39], which is important for the overall benefit/risk balance of MTX.
3.1.4. MTX haematologic toxicity
In respect of haematologic toxicity, the main recognised risk factors of MTX therapy are renal 
impairment, advanced age, absence of folate supplementation, drug interactions as well as 
medication errors. Given that most part of the data on myelosuppression has been derived 
from patients with rheumatoid arthritis, the relative risk of myelosuppression in MTX treat‐
ment for psoriasis may only be inferred. Current literature suggests that, in properly moni‐
tored psoriasis patients and in the absence of risk factors for haematologic toxicity, cases of 
clinically significant myelosuppression only rarely occur. Even with low‐dose weekly MTX, 
however, rare, pancytopenia and significant cytopenia are a permanent possibility in the 
presence haematologic risk factors, impaired renal function or even medication errors [40, 
41]. This once again speaks for the importance of regular monitoring of haematologic toxic‐
ity by complete blood cell counts. For patients without risk factors, the monitoring routine 
should consist of a first repeat laboratory check within a 2‐week period. Taking into account 
the possibility of pancytopenia in 4–6 weeks after increase of the MTX dose, as reported in 
some cases, monitoring should become more frequent in dose changes; in fact, according to 
some experts’ opinion, complete blood cell counts should be best undertaken at least every 
4 weeks [29]. Overtime and in patients with consistently stable conditions, the frequency of 
laboratory monitoring may decrease to 1–3‐month intervals.
Given the higher significant renal impairment risk even at single weekly MTX doses, the glo‐
merular filtration rate should be calculated even for patients with normal blood creatinine 
and urea nitrogen levels but at renal insufficiency risk because of age or decreased muscle 
mass considerations. In patients with known or at risk of impaired kidney function, careful 
monitoring should be a permanent concern and second doses or any dose increases should 
only be given after prior laboratory checks.
As medication interactions are an important source of adverse effects as well, in order to 
avoid error, patients should routinely be instructed to the proper use of MTX therapy.
3.1.5. MTX hepatotoxicity
In respect of MTX hepatotoxicity, the issue of liver biopsy has remained a subject of debate 
among physicians involved in MTX therapies for both rheumatoid arthritis and psoriasis. The 
opinion prevails among rheumatologists that, particularly in healthy patients, liver biopsy 
is not necessary [42]. To that stricter dermatology guidelines argue that hepatic toxicity is 
greater in psoriasis patients, partly relying on the confirmed higher incidence of rheumatoid 
arthritis among women, less in the habit of alcohol consumption and therefore at liver dam‐
age risk than men. On the other hand, as confirmed by recently published updates, higher 
liver damage incidence for psoriasis patients results from common risk factors such as obe‐
sity, diabetes, alcoholism as well as previous exposure to hepatitis and liver toxins [42–45]. 
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This is corroborated with histopathologic features of MTX‐induced liver toxicity, which are 
roughly similar to the liver histology pattern common in hyperlipidemic, obese or diabetic 
patients or to non‐alcoholic steatohepatitis (NASH). Clinical practice has in fact shown that, 
compared to no‐risk psoriasis patients, NASH risk factors likely aggravate pre‐existing NASH 
and eventually contribute to development of liver fibrosis even at lower MTX cumulative 
doses for psoriasis therapy. Such risk factors may represent inherent psoriatic patient pheno‐
types increasing hepatotoxicity risk. Provided controls of such confounding variables were 
introduced in studies conducted, MTX‐associated liver injury rate in psoriatic patients would 
probably be roughly similar to that encountered in rheumatoid arthritis patients [43, 46, 47]. 
All the above come to highlight that the necessity of the liver biopsy is a matter of individual 
patient condition and medical background and should be judged on a case‐by‐case ground.
As current guideline standards recommend for practice, based on their risk factors for liver 
injury, patients intended for MTX therapy should be divided into two groups, i.e. no‐risk 
versus risk patients. In the former group, the risk of fibrosis is lower and similar to rheuma‐
toid arthritis, which makes them eligible for application of ACR criteria for MTX monitoring 
(i.e. liver function evaluation every 1–3 months and liver biopsy in the case of elevation of 
5–9 serum AST levels over a 12‐month period or of serum albumin decline below the normal 
range against normal nutritional status and well‐controlled disease), a practice‐validated rou‐
tine schedule allowing for safe reduction of biopsies performed [48].
According to other recent data, the first liver biopsy in patients without pre‐existing hepa‐
totoxicity risk factors should be performed on use of a 3.5–4.0 g in place of the 1.0–1.5 g 
cumulative MTX, routinely recommended for pre‐existing risk factors [43, 49, 50]. In low‐risk 
patients on MTX, for normal values found in history of liver conditions, physical examina‐
tion and liver laboratory tests, the decision whether or not to perform liver biopsies should 
be individual and rely on relative risk evaluation. Further monitoring options for patients on 
3.5–4.0 g cumulative dose consist of application of ACR guidelines and continued monitoring 
with no biopsy, conduct of a first biopsy at the 3.5–4.0‐g level, or stopping MTX altogether 
or, if feasible, switching the therapy to some alternative treatment, if possible. In the case of 
normal results in the first biopsy, further liver biopsies in low‐risk patients are conducted in 
line with the ACR guidelines‐recommended timeframes.
It is generally agreed that management of patients with one or several hepatic fibrosis risk 
factors should be conducted in line stricter guidelines. Therefore, the presence of significant 
risk factors should first of all trigger consideration of the feasibility of therapy consisting of a 
different systemic agent. Next, a risk/benefit evaluation should be undertaken for each indi‐
vidual risk patient, to weigh the benefits against the risks of MTX therapy.
In the case of likely MTX benefits exceeding possible risks, liver biopsy is advisable on incep‐
tion of the therapy. Biopsy results permitting, MTX may be started although, in a small num‐
ber of patients, it would likely stop in 2–6 months after initiation mostly because of adverse 
effects or lack of clinical efficacy. In light of this possibility, the pre‐treatment liver biopsy may 
be postponed until after this ‘trial’ period, as there are no data indicative of clinically signifi‐
cant liver disease triggered by short or several‐month MTX treatment. In the case of antici‐
pated long‐term therapy or for patients with persistent significant abnormalities in laboratory 
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liver values, the initial biopsy is recommendable. In patients with acknowledged risk factors 
for liver disease, the liver biopsy should be repeated at a 1.0–1.5 g cumulative dose. Higher 
risk patients also require repeated biopsy with every MTX additional 1.0–1.5 g. However, as 
liver biopsy is not without risks, the procedure may not be appropriate or may be referred 
to another time in case, for the individual in question, risks of the biopsy per se outweigh the 
benefits; anyway, the risk of advanced fibrosis and that of liver biopsy complications should 
be carefully balanced.
However, although an important matter in itself, there is no screening tool for liver fibrosis 
available, allowing for relatively safe and effective decision on whether or not to use liver 
biopsy in the management of patients on MTX or at least decrease its need. Various other 
means have been tested in that respect, such as ultrasonographic tests and radiographic 
imaging techniques, but these have been mostly unsuccessful. More recently, measurement 
of a potential marker has been also tried, i.e. the amino‐terminal peptide of procollagen III 
(PIIINP), and comparative results have shown a sevenfold decrease in the number of biopsies 
in the group managed with application of the Manchester PIIINP guidelines as compared to 
the group for which the 1998 American Academy of Dermatology guidelines were applied 
[51]. Such results were later supported by an additional study showing the possibility of com‐
plete biopsy exclusion provided the PIIINP values remained stable [52]. Accordingly, this test 
is used as a monitoring tool for hepatic fibrosis by most practicing dermatologists in the UK 
and formal testing is currently put on hold in the US. One other additional aspect highlighted 
by the British study on PIIINP is the difference in characteristics among commercially avail‐
able PIIINP kits [53, 54].
Lately, the potential MTX‐associated hepatic fibrosis and cirrhosis have been shown to be 
considerably less aggressive than initially estimated [55, 56]. At the same time, there is 
an observable tendency for adverse events to mostly occur in patients with internal abnor‐
malities associated with other diseases. More specifically, risks such as gallbladder perfora‐
tion, hemoperitoneum subcapsular haemorrhage and pneumothorax are lower in psoriatic 
patients than in those with other diseases [57].
3.2. Therapies involving biological and biosimilars
In the same way as for rheumatoid arthritis, development of biologicals has been a ground‐
breaking event for the treatment of psoriasis, leading to unprecedented success in therapeutic 
approach of moderate‐to‐severe forms of psoriasis and psoriatic arthritis. In that respect, even 
if not considered first‐line treatments, biologic agents such as etanercept, adalimumab, inflix‐
imab and ustekinumab have been approved as second‐line therapies for psoriasis, whereas 
golimumab has been approved for psoriatic arthritis therapy.
Clinical practice with biologicals has revealed their higher efficacy and tolerability in com‐
parison to traditional systemic therapies [58], even in cases of refractory disease and expressly 
indicated for use in the so‐called high‐need patients, unresponsive or intolerant to all other 
available and approved systemic agents, MTX and cyclosporine included, or who cannot pos‐
sible use such conventional systemic agents for reason of pre‐existing disease [59].
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In addition, biologicals do not generally carry the same toxicity burden of toxic chemical or 
pharmacological adverse effects. Most related side effects are due to the specific biological 
properties of a given preparation, and result from neutralization of the biological activity of 
their target molecules, such as TNF‐α or IL‐12/IL‐23.
Psoriasis treatment can now rely on agents such as the TNF‐α antagonist etanercept, adali‐
mumab and infliximab, and on ustekinumab, a p40‐antagonist. An additional issue brought 
about by immunological properties of the novel biological therapies is the occasional need to 
switch between therapies because of immunological side effects such as severe local reactions 
or secondary loss of activity [60].
In fact, developments have been both rapid and uneven: on the one hand, biologicals men‐
tioned above are currently standard for a certain group of psoriatic patients, and specific 
guidelines have been developed [60, 61] whereas, on the other hand, in spite of their undeni‐
able usefulness, biological drugs are yet not in wide use for psoriasis treatment [61], partly 
because of practitioner's lack of awareness about their use for psoriasis and more importantly 
because of their comparative high costs.
This issue of cost effectiveness (the same benefit obtained with lower treatment costs) has 
prompted development of biosimilar alternatives following expiry of patents for biologi‐
cals; thus, in the context of a cost minimisation process, the appropriate products would 
be determined by price only [59]. Such so‐called biosimilars as erythropoietin prepara‐
tions and growth hormones have been developed in recent years for use in certain indica‐
tions [62, 63]. In fact, an increasing range of pharmaceutical companies, mostly Asian, have 
already developed biosimilar drugs relying on evidence derived from controlled clinical 
trials [64].
In biosimilars, the therapeutic protein is obtained by recombinant technology, and its struc‐
ture is similar to that of the original biological product (‘the reference drug'); this accounts for 
their very name—'biosimilars'. In addition, the pharmacological effects of the biosimilar as 
well as its mechanism of action are presumed identical to those of the reference [65].
If compared to drugs developed by chemical synthesis, the molecular weight of biosimilarsis 
is higher and their molecular structure is very complex. Although identical to amino acid 
sequence, their tertiary and quaternary structures may be heterogeneous, impacting their 
respective efficacy and safety profiles. Although similar in concept, biosimilars as copies of 
biologicals and generics as copies of chemically synthesized drugs must be treated in the 
same way, a fact clearly recognised by regulatory measures for assessment of preclinical data 
of both the EMA and the FDA.
In the same way as for generics and original drugs, since their very proposal as alternatives, 
the issue has been raised with regard to the extent that a structurally similar imitation of 
a drug could actually present identical efficacy and safety as the original [66]. It has been 
argued that variations in manufacturing processes may result in alterations of clinically rel‐
evant properties, likely to affect the finished product and subsequently monoclonal antibod‐
ies. But even if successful in part only, biosimilars would lead to significant reduction in drug 
costs as well as to a re‐structuring of the pharmaceutical market.
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The limitations of biosimilars would thus consist of possibly diminished reduced efficacy 
and higher risk potential from new side effects arising from such manufacturing variations 
[67]. Critical assessment of functional differences between biosimilars and their reference 
biological drug is essential for successful therapy and treatment safety.
Biosimilars display several biological characteristics, giving rise to specific consequences for 
clinical use. In biologicals and accordingly in biosimilars as well, proteins are formed by pro‐
tein folding, resulting in a complex three‐dimensional structure [65]. The biotechnological 
manufacturing process may induce batch‐to‐batch variations in the tertiary and quaternary 
structure even within a single production line [53, 65]. In addition, change in conditions at the 
manufacturing site or even switch from one site to another have often negatively impacted 
the quality and stability of biological drugs (according to [68]). The case has become known 
of the transfer to a company's new facility of the manufacture of efalizumab, a biological drug 
specifically designed for psoriasis treatment, which induced differences of such a scale in bio‐
logical characteristics that prompted an FDA request for new phase III study meant to assess 
and reconfirm bioequivalence [69].
Such clinically relevant variations in manufacture of a biosimilar have also been reported for 
erythropoietin, for instance, with the alteration of protein characteristics, resulting from dif‐
ferent properties of ionic bonding [70].
Respective risk of the modified therapeutic effect is even greater in the case of biosimilars 
introduced as a de novo production line.
However, the reverse is also true, and biosimilars may have improved properties in compari‐
son to the original, and this is the case of the so‐called biobetters, provided improvements are 
subjected to systematic research and implementation.
With regard to the ability of biological drugs to elicit an intended or unintended immunologi‐
cal response (immunogenicity), this is of special importance for this type of medicines, due to 
their marked immunogenic capacity resulting from their molecular structure (protein, poly‐
peptide) [71]. Typically, the immunogenicity and biological functions of proteins are a result 
of both covalent bonds and their native tertiary structure [72]. From the perspective of bio‐
similars, though not yet fully demonstrated, it cannot reasonably be assumed that alterations 
to the tertiary structure, however structurally minimal but significant as regards function, 
are unable to determine changes in immune responses, giving rise to autoimmune or allergic 
complications [70, 72–74]. On the other hand, the possibility also exists for the biological drug 
to prove excessively effective or become inactivated form of an immune reaction.
In the context of the high specificity of processes for the manufacturing of biologicals, they 
cannot possibly be fully replicated for manufacture of their biosimilars. The differences may 
arise from various sources, such as selection of production site as well as of cell lines, the 
manner of cell nutrition, fermentation conditions, the production temperature and environ‐
ment, etc. [66] and they can each alter the recombinant drug's effectiveness, stability and 
tolerability [75, 76]. Even when subjected to close monitoring and careful compliance with 
strict quality in the production process, variability in product quality (i.e. the integrity of the 
finished product) cannot be routinely excluded [77].
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In addition, variability of biological activity may also derive from its marked sensitivity to 
such environmental physical conditions as phases, temperature or shearing forces, to changes 
in the manufacturing process resulting in variable enzyme activity as well as to formulation 
changes [78]. Under the circumstances, it may reasonably be assumed that the drug's safety 
may also undergo some degree of influence and safety studies are therefore needed to test 
their behaviour in everyday use [79, 80].
In order to specifically determine the implications for clinical practice with biosimilars in 
psoriasis treatment, longitudinal studies are necessary, which has prompted both dermatolo‐
gists and rheumatologists to require study of biosimilars in long‐term registries as per their 
indications for use [68, 81]. An initiative in the respect is the PsoBest, conducted in Germany 
[82] as well as worldwide, with comparable registries [83, 84].
To counteract the possibility of diminished reduced efficacy and higher risk potential from 
new side effects in biosimilars, as early as 2004, the European Medicines Agency (EMA), 
followed by the U.S. Food and Drug Administration (FDA) developed legal and regulatory 
requirements (the consolidated Directive 2001/83/EC) and guidelines applicable to their 
development, evaluation and marketing, based on submission of preclinical data and clinical 
characteristics. As the time for patent expiry for biological drugs approved for psoriasis treat‐
ment draws nearer (e.g. the U.S. patents for etanercept was issued in 2012, for adalimumab in 
2016 and infliximab in 2014), the market will be open for biosimilars, which requires urgent 
clarification of actual meaning and implications for healthcare regulation in general and for 
dermatology in particular. Therefore, a description is useful related to future introduction of 
biosimilars in the treatment of psoriasis and psoriatic arthritis, making use of current regula‐
tory requirements and published data.
The same as for conventional medication, EU regulations require authorisation of biologi‐
cals and biosimilars. Centrally, scientific assessment is conducted by the European Agency's 
Committee for Medicinal Products for Human Use (CHMP) [85]; assessment may result in 
a recommendation on whether the medicine should be marketed, adopted by the EMA and 
transmitted to the European Commission which grants a marketing authorisation, applicable 
to all EU member states.
However, when it comes the evaluation of clinical bioequivalence, the EMA and the FDA 
have different perspectives: the EMA only requires evidence of pharmacodynamic and phar‐
macokinetic equivalence, with additional evidence of clinical bioequivalence from random‐
ized clinical studies being necessary in uncertain cases only [68], whereas the FDA insists on 
bioequivalence being supported by clear factual information, resulting from clinical studies.
The EMA and FDA approaches for post‐marketing surveillance are similar in that both 
require conduct of non‐interventional safety trials after marketing.
EMA guidelines have been developed in relation to the quality of biologicals, stating preclini‐
cal and clinical requirements, as well as product specifications [76–88]. According to EMA 
guidelines, biosimilars should be deemed specifically different from generics and use of 
approval procedures for generics is prohibited in relation to biosimilars. Further provisions 
regard the manufacturer's obligation to conduct clinical studies [89] seeking to demonstrated 
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similarity of quality, safety and efficacy between the biosimilar and its biological reference 
drug. The same similarity must apply to the formulation, concentration and mode of admin‐
istration of the therapeutic substance. Such data are derived for assessment purposes from 
preclinical experiments, both in vitro and in vivo, as well as from clinical studies conducted on 
patients or healthy volunteers; however, the amount of data required for biosimilars is less 
extensive than for the original biological.
At the same time, the biosimilar manufacturer is required to submit a risk management plan, 
focusing on safety specifications as well as a pharmacovigilance plan and a risk minimisation 
plan.
A further regulatory request for biosimilars is that they should allow for clear identification, for 
instance by use of distinct brand names or non‐proprietary names, which allow for clear docu‐
mentation, particularly in what concerns reports of potential adverse reactions and side effects.
The EMA's appointed (co)‐rapporteurs undertake a scientific assessment of the documen‐
tation submitted in support of the application for biosimilar authorisation, on a case‐by‐
case basis. Positive assessment opinion results in grant of a marketing authorisation by the 
European Commission.
Provided certain conditions are met, the EMA allows for extrapolation of initially approved 
clinical indications for which they can provide evidence. This is of particular importance for 
psoriasis, which, because of the widely varying characteristics of the disease, patient fea‐
tures and similarities of risk profiles between psoriasis and rheumatoid arthritis, for instance, 
requires critical evaluation of claims of analogies between indications [81, 90, 91].
Exchangeability and substitution are also of importance with regard to the biological refer‐
ence drug‐biosimilar relation; exchangeability is the term used to refer to the possibility of 
replacement based on medicinal and pharmaceutical characteristics between a drug devel‐
oped for a specific indication and a different substance with identical effects. This is only 
feasible when the substitute drug has same quality, safety and efficacy features as the substi‐
tuted one. In pharmaceutical practice in Germany, for instance, drugs may be substituted if 
the substitute has been approved in relation to reference product, and no difference could be 
established with regard to original substance or their manufacturing process. In that context, 
taking into account the differences in manufacturing processes of biosimilars and their result‐
ing immunological and pharmacological characteristics, identity with the reference in terms 
of active ingredients may be ruled out [92].
Currently, the clinical consequences of repeated substitutions with biosimilars, either between 
themselves or for a biological, are only reviewed in few clinical studies [92]. This has prompted 
the EMA recommendation that the decision as to which of the two, the original biological 
drug or its biosimilar, should be given should be the sole choice of the treating physician. 
This has been preceded by measures of national authorities such as the Drug Commission of 
the German Medical Association, which has issued a warning against substitution of biotech‐
nological drugs for one another in the absence of medical reviews. Substitution of an original 
biological product with its biosimilars is only possible on explicit request by the patient's 
physician.
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Also pertaining to substitution and exchangeability, one very important aspect is that, partic‐
ularly where patients with chronic disease and clear immunological origins such as psoriasis 
are involved, uncontrolled product switching and the so‐called ‘product hopping’ should be 
avoided.
With regard to the pharmacovigilance aspects of biologicals and biosimilars, their total range 
of immunogenicity and associated reactions remains yet to be researched and described: data 
from clinical studies and trials need to be complemented with information from actual health‐
care practice [93]. The capacity of biosimilars to induce immune responses needs to be stud‐
ies after their actual placement on the market and the same pharmacovigilance provisions 
should apply to biosimilars as to their reference. This obligation requires conduct of post‐mar‐
keting studies, mainly designed as controlled patient registries. In that respect, the EMA has 
also developed a comprehensive post‐marketing pharmacovigilance program applicable to 
biosimilars, consisting of performance of a post‐marketing safety study and implementation 
of a risk management plan, including:
 ‐ Spontaneous reporting of potential side effects associated with use of a biosimilar after 
their reporting by patients themselves or healthcare professionals;
 ‐ Preparation of Periodic Safety Update Reports (PSURs);
 ‐ Preparation of post‐authorisation safety studies (PASS) (also known as phase IV studies) 
[94].
Pricing issues are also relevant for biosimilars, which, although considered less costly in 
comparison to their biopharmaceutical reference, because of the considerable research and 
development financial investments (currently, 80–120 million Euros), to which costs of bio‐
technological production sites must be added, do not in fact bring about a very great differ‐
ence as price is concerned (not exceeding 20–25% less than the biopharmaceutical reference).
All the aspects considered, introduction of biosimilars into therapy, psoriasis treatment 
included, will undergo constant increase after patent expiry for original. The process will how‐
ever increase the need for information from healthcare professionals, carers and patients alike.
4. MTX therapeutic benefits versus toxicology emergencies
In psoriasis therapy, low MTX doses are rarely associated with toxicity, and in most cases this 
only occurs because of non‐compliance with the recommended guidelines [95].
However, the risk of MTX toxicity increases when additional MTX is administered sooner 
than provided for by the routine planned weekly dose [96], as, for instance, in the case of out 
of self‐administration outside therapeutic protocol of a higher, consecutive dose, acting as 
precipitating factor.
MTX toxicity may be observed by its effects on the skin (ulcerations), the gastrointestinal 
mucosa, as well as at liver, kidney and bone marrow levels. Limitation of toxicity‐related skin 
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ulcerations to psoriatic plaques is likely the result of higher MTX uptake by the hyperprolif‐
erative psoriatic plaques as compared to the normal skin. The influence of toxicity may be 
assessed by both evaluation of change of membrane fluidity at the cellular level [97, 98], as 
well as in vivo, by confocal microscopy [99].
MTX‐induced pancytopenia may occur in renally impaired patients as well as in cases of folic 
acid deficiency, infection and hypoalbuminemia but also as a result of concomitant drug use 
(e.g. trimethoprim) and advanced age [100].
Additional features of MTX toxicity are mucositis and myelosuppression, the likely cause of 
the latter being advanced age [101], concomitant NSAID use and careless use of the prescribed 
MTX dose; in other cases, this may be a result of renal dysfunction not identified prior to 
treatment initiation. However, inadvertent MTX dosage is the major contributory factor for 
MTX toxicity found in clinical practice, which strongly speaks for mandatory avoidance of 
MTX self‐administration and appropriate patient instruction in that respect as well against 
combination of MTX with other drug without prior medical counselling.
MTX toxicity potential may be enhanced by use of generally renotoxic drugs which either 
decrease MTX renal elimination (e.g. cyclosporine, aminoglycosides, nonsteroidal anti‐
inflammatory agents, probenecid, sulfonamides, salicylates, colchicines, penicillins and cis‐
platin) or induce MTX displacement from protein binding sites in the plasma (as is the case of 
salicylates, sulfonamides, probenecid, phenytoin, barbiturates, sulfonylureas, retinoids and 
tetracyclines). Use of NSAID for joint pain can contribute to MTX toxicity.
Methods for MTX quantification also exist, as both a parent compound and mostly as MTX 
polyglutamate forms, responsible for its effect [102, 103].
To avoid toxicity, over‐the‐counter availability of MTX should be prohibited.
5. Discussion
Development of biological medicines has brought about new therapeutic options for psoriasis 
and other inflammatory diseases, which have proved successful in the therapy of moderate‐
to‐severe and severe forms of plaque psoriasis alike.
Although giving rise as novel therapeutic agents to concerns related to their efficacy and 
safety, innovative pharmacobiologicals such as etanercept, adalimumab, infliximab, ixeki‐
zumab, ustekinumab and secukinumab, to mention a few, clinical practice has proved their 
short‐ and long‐term efficacy and remarkable tolerability.
The process is currently replicated with regard to emerging biosimilars, developed for treat‐
ment of the same conditions as their original reference. Suspicions as to their safety and effi‐
cacy should be lifted by the undeniable outcomes derived from in‐depth clinical trials already 
conducted and clinicians should more resolutely make use of their demonstrated capacities.
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In an overall context of unmatched medical and pharmacological development, mainly char‐
acterised by the uniquely fast pace of research and findings in the area of biologicals and 
biosimilars, these currently play a remarkable role in advanced medicine. However, this has 
also raised a challenge for both international researchers, developers, manufacturers and 
for other drug‐related regulatory fields such as the development of standards and pharma‐
covigilance, as the most important. This is further enforced by the expectation that, at least 
in Europe, biosimilars would lead to 15–30% cost reduction in use of biological therapeutic 
agents.
With regard to the therapeutic benefits‐toxicological emergencies ratio particularly in psoriatic 
patients, there is a common concern related to possible association of MTX therapy with toxic‐
ity in various forms, of which some are serious and, in rare cases, may even include patient 
death.
Because of their implication for clinical practice, two aspects should be particularly outlined 
in relation to MTX toxicity: firstly, there is their potential to manifest at any time during the 
treatment, which calls for constant monitoring; secondly, the importance of the MTX dose or 
the dosing frequency for determining the risk for both toxicity and its severity.
MTX‐induced toxic effects of special concern are severe skin reactions, hepatotoxicity (with 
both acute and chronic forms, with liver fibrosis and cirrhosis), acute haematological toxicity, 
lymphoproliferative disorders and severe opportunistic infections, lung disease and serious 
gastrointestinal toxicity.
Given this relatively high‐risk context, further complicated by the additional threat posed by 
the potential for serious cumulative toxicity, MTX therapy is generally to be used mainly for 
patients with severe psoriasis, whose quality of life is seriously affected by their disease as 
well as for cases where proper disease control cannot be accomplished by use of topical thera‐
pies. As a further minimisation measure, MTX dose reductions and off‐treatment periods 
should be applied whenever possible.
Undeniably, a therapeutic advantage due to relatively low costs of therapy complemented 
by ease of oral administration, in the presence of potential to achieve reasonable safety and 
tolerance, use of MTX has to be considered against its serious toxicity potential, which may be 
kept under control by careful patient selection and individual assessment of the benefit‐risk 
balance for each psoriasis patient, accompanied by routine monitoring and strict compliance 
with monitoring guidelines.
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